Comments
Suven Life Sciences Tuesday said it has been granted a product patent each by Israel and Japan, for a new chemical entity (NCE) that is used in the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2036 and 2034 respectively, the company said in a BSE filing.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the Central nervous system (CNS) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
The granted claims of patents are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson’s and schizophrenia, it added.
Shares of Suven Life Sciences were trading 0.56 per cent up at Rs 242.10 apiece on BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.